chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I experience shooting pain in my upper left arm and shoulder especially at night when I'm sleeping. This went on for about 10 days it is slowly getting better but I still experience pain when raising my left arm and doing any weights that focus on my shoulder or tricep.
Severe shoulder pain, nausea, headache, rash across chest, neck, arms, back and abdomen.  Fever of 100.
This spontaneous report was received from a female consumer of unknown age reporting on herself. The patient's medical history and concurrent conditions were not reported. Six months ago on an unspecified date in December 2016, the patient was administered an unspecified dose of ZOSTAVAX, subcutaneously, (concentration, dose lot number and expiration date were not reported) by an anonymous health care provider. Concomitant therapies were not reported. The patient was administered unspecified steroids for her back disorder on MAY-01-2017 and then reported that the unspecified steroids did not work and she thought that maybe it was because of the ZOSTAVAX. The patient has not consulted her physician. The patient stated that at the time of the report, she had not recovered. Additional information has been requested.
pt recv vax 9JUL96 & devel bells palsy on 7AUG96;
SYNCOPE, FAINTED AND HIT HEAD ON POLE, SMALL CUT ON SIDE OF FOREHEAD
chills in the arm; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills in the arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHILLS (chills in the arm). At the time of the report, CHILLS (chills in the arm) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.  No relevant concomitant medications were reported.  No treatment information was provided.
Dizziness, Weakness, feeling of impending doom, Shaky, tremor like movements. A/O no loss of consciousness, no SOB, pain, nausea, vomiting.
had both shots and now I get the breakouts/ suspected vaccination failure; breakouts; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. The patient was treated with eucalyptus. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient. The age at vaccination was not reported. The patient received both shingles shots and now get the shingles breakouts more often. The patient had started using eucalyptus on shingles and stated that they sell eucalyptus at walmart. This case was considered to be a suspected vaccination failure case, as the details regarding laboratory confirmation for shingles and time to onset were unknown.
temperature 100.5; She has body aches all over including her hips and joints; eyes burning; Headache; Chills; This is a spontaneous report from a contactable consumer (patient himself) A 55-year-old female consumer patient received the second dose of BNT162B2 (Solution for injection, lot number: EL3249, Expiration date; unknown), in Left arm on 02Feb2021, 9:30 AM at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient historical vaccine included first dose BNT162B2 (lot number: EL1283) left arm on 12Jan2021, at single Covid-19 immunization. The patient experienced Last night the caller started having chills on 02Feb2021 and end of reaction/event on 03Feb2021, the outcome of event of chill was recovered. Patient having temperature of 100.5, body aches to a bad toothache all over body including her hips and joints, eyes were burning might be from the temperature and headache on 03Feb2021. The outcome of the events was not recovered.  Follow-up activities have been completed and no further information is expected.
Fever (102.7), headache, soreness of arm, lymphnode swelling (axilary), tea colored urine (prior to rehydration), cotton mouth. Tx: ACTM PRN over 3 days for fever,  Increased fluids
Fever, pain..redness..swelling injection site, nausea, vomiting, headache, exhaustion, body aches Resolved after 2 days.  8 days later woke up with pain..redness..swelling injection site, nausea, headache again
Patient was brought by her father to a mass vaccination clinic on 5/13/21. At this time, patient was 13 years old. Father requested that patient receive Moderna, volunteer vaccinator gave Moderna vaccine. Patient's mother, brought her to the second dose appointment. Confirmed that father requested Moderna and that is the product that patient received. Discussed error with RN, vaccine coordinator. Plan to complete Moderna series, appointment for second dose rescheduled for next week for appropriate dose spacing. Mother and patient both deny any reaction or ill effects related to receiving Moderna vaccine. Mother is aware that error will be reported to VAERS.
Shortness of breath/hard to breathe; Dizziness; fast heart rate/heart is palpitating faster than normal; weak and dizzy; panic attacks; Shortness of breath was reported as worsened/Dizziness was reported as worsened/fast heart rate was reported as worsened/weak and dizzy was reported as worsened; This is a spontaneous report from a contactable consumer (patient). A 45-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 1 via an unspecified route of administration, administered in the left arm on 05Mar2021 (Batch/Lot number was not reported) as dose 1, single (at the age of 45-years-old) for Covid-19 immunisation. Medical history included high blood pressure - diagnosed over a year ago. Concomitant medication included losartan (LOSARTAN) taken for high blood pressure, start and stop date were not reported. The patient called about the side effects of Covid vaccine, stated he took the first dose of the vaccine on Friday 05Mar2021 and stated on Saturday and Sunday, he had symptoms. He stated that his problem is that his heart is palpitating faster than normal, it is hard to breathe, and he gets weak and dizzy. He also said it has gotten worse but comes and goes. He has been to his doctor, the doctor told him that it was not caused by the vaccine that he is having panic attacks. The patient did not get a patient card for vaccine info, unable to confirm product details like manufacturer, NDC, Lot and Expiration. The patient wanted to know if he should go to the emergency room. The events had not resolved at the time of the report. The events required a physician office visit.   No follow-up attempts are possible; information about batch/lot number cannot be obtained. No further information is expected.; Sender's Comments: As per available information, the event panic attacks and the suspect drug BNT162B2 are assessed as  not related.
Headache around 15 minutes after shot, dizziness,  nausea, racing heart, dilated pupils at 29 minutes after shot.
Patient stated she felt flushed and her skin was warm and moist. Patient reported having pressure in her chest.
I did take the Shingles vaccine/Suspected Vaccination Failure; but still got Shingles.; miserable rash; burning; itching; soreness, worst pains; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: I did take the Shingles vaccine/Suspected Vaccination Failure) (serious criteria GSK medically significant), shingles (Verbatim: but still got Shingles.), rash (Verbatim: miserable rash), burning sensation (Verbatim: burning), pruritus (Verbatim: itching) and pain (Verbatim: soreness, worst pains). The outcome of the vaccination failure was unknown and the outcome of the shingles, rash, burning sensation, pruritus and pain were not reported.   It was unknown if the reporter considered the vaccination failure, shingles, rash, burning sensation, pruritus and pain to be related to Shingles vaccine.   It was unknown if the company considered the vaccination failure, shingles, rash, burning sensation, pruritus and pain to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 08-MAR-2023  This case was reported by a patient via interactive digital media. The reporter stated that one of the worst pains that he/she had ever experienced.  The patient had just gotten through his/her second time with the miserable rash, burning, and itching, not to mention soreness. The reporter further stated that it was a terrible disease that you would get and was difficult to treat and injections and cream only helped until it ran its course.  The patient did take the shingles vaccine a few years ago too but still got Shingles. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow up would not possible as no contact details were available.
information has been received from a consumer concerning her 19 year old daughter who on 22-FEB-2007 was vaccinated with her second dose of HPV. Concomitant therapy included unspecified birth control. On 22-FEB-2007 the patient experienced "a lot of pain and was in tears" after receiving HPV. Unspecified medical attention was required. It was also reported that the patient experienced "a little pain" after the first dose of HPV was administered. At the time of the report, the patient's pain persisted. Additional information has been requested.
Swollen chin, severe itching and bumps on head, neck, buttocks, the palm of hand, forehead
This spontaneous report was received from a registered nurse refers to multiple unspecified patients of unknown age and gender. Medical history, concurrent conditions and concomitant medications were not reported. On unspecified dates, the patients were vaccinated with improperly stored PNEUMOVAX 23 lot/batch # L040178, expiry date 18-AUG-2017 (dose, strength, vaccination site and route unspecified). The temperature excursion was reported as 34F for 48 hours. No adverse effect were reported. Product quality complain (PQC) was not involved. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a pharmacist concerning a female patient who on an unknown date was vaccinated with ZOSTAVAX (Merck) (dose, route and lot # not reported). The pharmacist reported that on an unspecified date the patient who received ZOSTAVAX (Merck) was experiencing hot flashes and sweating. It was unspecified that if the patient sought medical attention. Additional information has been requested.
The caller went on to ask about another AE where a "6 year old patient received meningococcal vaccine and they were outside the age requirements; No additional AE reported.; This spontaneous report has been received from a nurse prescriber, referring a 6-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant medications were not provided.  On an unknown date, the patient was vaccinated with a dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) intramuscular injection (strength, dose, frequency, administration route, lot number, and expiry date were not provided) (product administered to patient of inappropriate age) indicated as prophylaxis.  No additional adverse events were reported.  This is one of several reports received from the same reporter; Sender Comments:  US-009507513-2303USA006657:Original Case : 2303USA006657
p/vax pt exp mild redness,soreness that resolved;31JUL95 pain in rt hand near arm;zit noted @ site of vax;pain,chills,redness,edema of deltoid muscle;sx persisted severe pain;required extensive physical therapy
At 3:00 pm the day after I received the Johnson&Johnson COVID-19 vaccine I developed a red, raised, swollen, hot, painful circle 5'' in diameter on my left arm under the injection site. My arm is hot to touch, swollen, and still painful the next day and the circle has spread more and has started to turn purple.
She lost hearing in her right ear; Dizzy; A spontaneous report was received from a consumer concerning a 54-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced lost hearing in her right ear, dizziness.   The patient's medical history was not provided. Concomitant product use was unknown by the reporter.  On an unspecified date, the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) via unknown route and site for prophylaxis of COVID-19 infection.   On an unspecified date, the patient received their second dose of mRNA-1273 (Lot number: unknown) via unknown route and site for prophylaxis of COVID-19 infection.  On an unspecified date, the patient experienced lost hearing in her right ear, dizziness.   Treatment for the events included prednisolone.  Action taken with mRNA-1273 in response to the events is not applicable.   The outcome of events, lost hearing in her right ear, dizziness were unknown.; Reporter's Comments: Very limited information regarding the events have been provided at this time.  Patient's medical history, therapy dates, onset dates of events, clinical evaluation are lacking  Further information has been requested.
pt recv vax 5AUG98 & w/in 2 days post vax pt exp arthralgia presented to a Md & was treated w/NSAID;arthralgia persisted;
Rash from injection site and all over abdomen and torso, moving up the neck to the face.  Treatment was 2.5ml of Zyrtec to treat the rash.
This spontaneous report as received from an unspecified reporter refers to a patient of unknown age and gender. On 13-OCT-2014, the patient was vaccinated with MMR II (route, dose, frequency and lot # not reported) which underwent an excursion (on an unspecified date). This is one of several reports from the same source. Additional information has been requested.
symptoms returned on Friday through Sunday; COVID 19 Treatment; COVID 19 Treatment; vaccine_brand=Pfizer / BioNTech, vaccine_administration_date=24/Nov/2021,; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 57-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 24Nov2021 as dose 2 (booster), single (Lot number: FH8030) at the age of 57 years, in left arm for covid-19 immunisation; coviD-19 vaccine nrvv ad26 (jnj 78436735) (JANSSEN COVID-19 VACCINE), on 10Mar2021 as dose 1, single (Lot number: 1802072), in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Past drug history included: Erythromycin for Known allergies: Erythromycin. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 24Nov2021, outcome "unknown", described as "vaccine_brand=Pfizer / BioNTech, vaccine_administration_date=24/Nov/2021,"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Aug2022, outcome "unknown" and all described as "COVID 19 Treatment"; SYMPTOM RECURRENCE (medically significant) with onset 26Aug2022 at 06:00, outcome "recovered" (28Aug2022), described as "symptoms returned on Friday through Sunday". Therapeutic measures were taken as a result of drug ineffective, covid-19. Therapeutic measures were not taken as a result of symptom recurrence. Clinical Course: Patient was treated with Paxlovid for COVID 19 Treatment from 18Aug2022 to 22Aug2022. Patient also reported that she had symptoms resolved after five days of Paxlovid, finished on a Monday. She continued to isolate/work from home and symptoms returned on Friday through Sunday.  No follow-up attempts are possible. No further information is expected.
Noticed heavy bruising and red dots on the skin.  Diagnosed with ITP - treated with IVIG in hospital.
CDC reports: 14 mo child experienced fever to 104 & two convulsive episodes following DTP/OPV immunization, hospitalized 1 day, child found to have mild ear infection on exam at hosp.
Gianotti-Crosti type papular rash 2-4 weeks after vaccine. Rash lasted greater than 6 weeks.
Yeast infection after getting my second dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of FUNGAL INFECTION (Yeast infection after getting my second dose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FUNGAL INFECTION (Yeast infection after getting my second dose). At the time of the report, FUNGAL INFECTION (Yeast infection after getting my second dose) outcome was unknown.            No concomitant medication were reported. No treatment information was reported.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was not applicable.   Reporter did not allow further contact
no adverse effects of the vaccination are documented, however 6 full doses of the vaccine were administered to the patient without knowledge of the administrator 1.8 ml of dillutent was injected into the vaccine vial, entire vial was drawn up and injected instead of 0.3ml. the vial was then found empty and assumed that the entire vial was used on one patient. patient, cdc, health department, poison control, and health care provider were all informed and asked for more information
Patient tested positive for covid 8/14/22 and treated with dexamethasone, azithromycin, and albuterol inhaler.  Patient came back to the ED 8/21/22 with persistent weakness, malaise, fatigue, sore throat, and cough.  Patient admitted to hospital for viral pneumonia from Covid.
Tenderness, redness past 3-4 day normal reaction. (1 week).
Pt received vaccine on 8/23, and the next day arm was swollen and whole upper left arm was bruised and blue.
A 44 yr old Caucasian female with a pollen allergy, hay fever, asthma,and environmental allergies who on 30-MAR-2000 was vaccinated with second dose of measles virus vaccine live and mumps vaccine rubella virus vaccine live (second generation) SC in the left arm. Other therapy included Fumotidine, induration and dose and indication unknown (MSD). Also given was Tylenol and Allegra. On 31-MAR-2000 experienced itching. On 03-APR-2000 the pt experienced a rash on the face and neck. The rash progressed to the trunk and limbs on 06-APR-2000. The pt also experienced pharyngitis. It was reported the Allegra did not help with itching. The pt was taken to the emergency room and a strep culture performed on 06-APR-2000 was negative. The pt recovered on 11-APR-2000.
Generalized rash, itching. Rx: Prednisone 20 mg x 5 days, Hydroxyzine 25 mg prn.
shingles; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 5 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The patient had shingles 5 days after receiving Shingrix. Consented to follow up.
Nausea after 3rd Monovalent shot; Dizziness after 3rd Monovalent shot; Fever 99F after 3rd Monovalent shot; /Monovalent (not sure if half dose) on 14AUG2021; This spontaneous case was reported by a patient and describes the occurrence of NAUSEA (Nausea after 3rd Monovalent shot), DIZZINESS (Dizziness after 3rd Monovalent shot), PYREXIA (Fever 99F after 3rd Monovalent shot), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd Primary monovalent dose on 09MAR2021/Monovalent (not sure if half dose) on 14AUG2021) and NO ADVERSE EVENT (No Adverse Event) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 088D21A) for COVID-19 prophylaxis.     Concurrent medical conditions included Cancer since 2019. Concomitant products included RITUXIMAB (RITUXAN) from an unknown date to 27-Apr-2022 for an unknown indication.    On 14-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd Primary monovalent dose on 09MAR2021/Monovalent (not sure if half dose) on 14AUG2021) and NO ADVERSE EVENT (No Adverse Event). On 14-Aug-2021, the patient experienced NAUSEA (Nausea after 3rd Monovalent shot), DIZZINESS (Dizziness after 3rd Monovalent shot) and PYREXIA (Fever 99F after 3rd Monovalent shot). On 17-Aug-2021, NAUSEA (Nausea after 3rd Monovalent shot), DIZZINESS (Dizziness after 3rd Monovalent shot) and PYREXIA (Fever 99F after 3rd Monovalent shot) outcome was unknown. In January 2022, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd Primary monovalent dose on 09MAR2021/Monovalent (not sure if half dose) on 14AUG2021) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.            Antibody tests on MAY2021 & JAN2022 showed no detectable antibody No Treatment Medication were provided by reporter.    This case was linked (Patient Link).